查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386998

放射性藥物治療市場報告：2030 年趨勢、預測與競爭分析

Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

放射性藥物治療診斷趨勢與預測

到 2030 年，全球放射性藥物治療診斷市場預計將達到 39 億美元，2024 年至 2030 年年複合成長率為 11.2%。該市場的主要促進因素是癌症發生率的增加和心血管疾病治療應用的增加。全球放射性藥物治療市場的未來前景廣闊，醫院、診斷影像中心以及學術和研究機構市場都有機會。

放射性藥物治療診斷市場洞察

Lucintel 預測 PET 示蹤劑將在預測期內達到最高成長。

由於技術先進的系統的可用性和醫院數量的不斷增加，醫院可能仍然是該市場中最大的部分。

由於慢性病的增加、放射性藥物和寵物掃描儀的容易取得，預計北美在預測期內將出現最高的成長。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2. 未來哪個細分市場成長較快？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球放射性藥物治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球放射性藥物治療市場趨勢（2018-2023）與預測（2024-2030）
  • 按產品類型分類的全球放射性藥物治療市場
    • α發射體
    • BETA發送器
    • PET示蹤劑
  • 全球放射性藥物治療市場（按來源）
    • 核子反應爐
    • 迴旋加速器
  • 按適應症分類的全球放射性藥物治療市場
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 其他
  • 按最終用途分類的全球放射性藥物治療市場
    • 醫院
    • 影像診斷中心
    • 學術研究所
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球放射性藥物治療市場按地區分類
  • 北美放射性藥物治療診斷市場
  • 歐洲放射性藥物治療診斷市場
  • 亞太地區放射性藥物治療診斷市場
  • 其他區域放射性藥物治療診斷市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按產品類型分類的全球放射性藥物治療市場成長機會
    • 全球放射性藥物治療市場成長機會（依來源）
    • 按適應症分類的全球放射性藥物治療市場成長機會
    • 按最終用途分類的全球放射性藥物治療市場成長機會
    • 按地區分類的全球放射性藥物治療市場成長機會
  • 全球放射性藥物治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球放射性藥物治療市場的能力
    • 全球放射性藥物治療市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Bayer
  • GE HealthCare Technologies
  • Curium
  • Lantheus Medical Imaging
  • Telix Pharmaceuticals
  • Cardinal Health
  • Advanced Accelerator Applications
  • Jubilant Radiopharma
  • Theragnostics
  • NuView Life Sciences
簡介目錄

Radiopharmaceutical Theranostics Trends and Forecast

The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets. The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030 with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

A more than 150-page report is developed to help in your business decisions.

Radiopharmaceutical Theranostics by Segment

The study includes a forecast for the global radiopharmaceutical theranostics by product type, source, indication, end use, and region.

Radiopharmaceutical Theranostics Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • Alpha Emitters
  • Beta Emitters
  • PET Tracers

Radiopharmaceutical Theranostics Market by Source [Shipment Analysis by Value from 2018 to 2030]:

  • Nuclear Reactors
  • Cyclotrons

Radiopharmaceutical Theranostics Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Cardiology
  • Neurology
  • Others

Radiopharmaceutical Theranostics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Diagnostic Imaging Centers
  • Academic & Research Institutes
  • Others

Radiopharmaceutical Theranostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Radiopharmaceutical Theranostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiopharmaceutical theranostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiopharmaceutical theranostics companies profiled in this report include-

  • Bayer
  • GE Healthcare Technologies
  • Curium
  • Lantheus Medical Imaging
  • Telix Pharmaceuticals
  • Cardinal Health
  • Advanced Accelerator Applications
  • Jubilant Radiopharma
  • Theragnostics
  • Nuview Life Sciences

Radiopharmaceutical Theranostics Market Insights

Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Within this market, hospitals will remain the largest segment due to availability of technologically advanced systems and rising number of hospitals.

North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Features of the Global Radiopharmaceutical Theranostics Market

Market Size Estimates: Radiopharmaceutical theranostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radiopharmaceutical theranostics market size by various segments, such as by product type, source, indication, end use, and region in terms of value ($B).

Regional Analysis: Radiopharmaceutical theranostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, sources, indications, end uses, and regions for the radiopharmaceutical theranostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiopharmaceutical theranostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the radiopharmaceutical theranostics market size?

Answer: The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030.

Q.2 What is the growth forecast for radiopharmaceutical theranostics market?

Answer: The global radiopharmaceutical theranostics market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the radiopharmaceutical theranostics market?

Answer: The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

Q4. What are the major segments for radiopharmaceutical theranostics market?

Answer: The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets.

Q5. Who are the key radiopharmaceutical theranostics market companies?

Answer: Some of the key radiopharmaceutical theranostics companies are as follows:

  • Bayer
  • GE Healthcare Technologies
  • Curium
  • Lantheus Medical Imaging
  • Telix Pharmaceuticals
  • Cardinal Health
  • Advanced Accelerator Applications
  • Jubilant Radiopharma
  • Theragnostics
  • Nuview Life Sciences

Q6. Which radiopharmaceutical theranostics market segment will be the largest in future?

Answer: Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Q7. In radiopharmaceutical theranostics market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the radiopharmaceutical theranostics market by product type (alpha emitters, beta emitters, and PET tracers), source (nuclear reactors and cyclotrons), indication (oncology, cardiology, neurology, and others), end use (hospitals, diagnostic imaging centers, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radiopharmaceutical Theranostics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Radiopharmaceutical Theranostics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Radiopharmaceutical Theranostics Market by Product Type
    • 3.3.1: Alpha Emitters
    • 3.3.2: Beta Emitters
    • 3.3.3: PET Tracers
  • 3.4: Global Radiopharmaceutical Theranostics Market by Source
    • 3.4.1: Nuclear Reactors
    • 3.4.2: Cyclotrons
  • 3.5: Global Radiopharmaceutical Theranostics Market by Indication
    • 3.5.1: Oncology
    • 3.5.2: Cardiology
    • 3.5.3: Neurology
    • 3.5.4: Others
  • 3.6: Global Radiopharmaceutical Theranostics Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Diagnostic Imaging Centers
    • 3.6.3: Academic & Research Institutes
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Radiopharmaceutical Theranostics Market by Region
  • 4.2: North American Radiopharmaceutical Theranostics Market
    • 4.2.2: North American Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
  • 4.3: European Radiopharmaceutical Theranostics Market
    • 4.3.1: European Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
    • 4.3.2: European Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
  • 4.4: APAC Radiopharmaceutical Theranostics Market
    • 4.4.1: APAC Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
    • 4.4.2: APAC Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
  • 4.5: ROW Radiopharmaceutical Theranostics Market
    • 4.5.1: ROW Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
    • 4.5.2: ROW Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Source
    • 6.1.3: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Indication
    • 6.1.4: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by End Use
    • 6.1.5: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Region
  • 6.2: Emerging Trends in the Global Radiopharmaceutical Theranostics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Radiopharmaceutical Theranostics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiopharmaceutical Theranostics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bayer
  • 7.2: GE HealthCare Technologies
  • 7.3: Curium
  • 7.4: Lantheus Medical Imaging
  • 7.5: Telix Pharmaceuticals
  • 7.6: Cardinal Health
  • 7.7: Advanced Accelerator Applications
  • 7.8: Jubilant Radiopharma
  • 7.9: Theragnostics
  • 7.10: NuView Life Sciences